星雲股份(300648.SZ):2021年度累計收到各項政府補助共1558.52萬元
格隆匯7月30日丨星雲股份(300648.SZ)公佈,公司及分公司、子公司,自2021年4月28日至公吿披露日累計各項政府補助資金共計人民幣863.34萬元(實際已到賬金額為人民幣592.42萬元),其中增值税即徵即退政府補助資金為人民幣496.72萬元(實際已到賬金額為人民幣225.8萬元),政府科研項目補助資金及其它政府補助資金為人民幣366.618萬元。政府補助的具體類型及其會計處理方法均根據《企業會計準則第16 號-政府補助》的規定確認及處理。截至公吿日,2021年度累計收到各項政府補助資金共計1558.52萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.